nia1001 anti clotting drug

Hemarthroses

Recurrenthemarthroses

The importance of rapid bleeding controlHemophilia patients with inhibitors present a special challenge

“ The time taken to stop a

bleeding episode is very

important to the patient

as it reduces the time

a patient is in pain, the

amount of hemostatic agent

required, the potential

long-term damage to the

joint, and the subsequent

cost of undergoing a joint

arthroplasty.”

The vicious cycle of joint damage8

In the long term, the presence of blood in the joint leads to chronic synovitis, development

of a target joint, and progressive arthropathy8

Difficult to manage4,5,6

Poorer outcome following joint bleeds7

Greater risk of long-term joint damage and disability7

Delaying treatment results in:10

- Longer time to bleeding resolution

- A larger number of doses required to stop the bleeding

- Increased costs

Clinical guidelines for hemophilia emphasise the importance of early intervention

NiaStase RT® acts here

NiaStase RT® (eptacog alfa, activated) is indicated in hemophilia A/B patients with inhibitors to FVIII or FIX, respectively, for the treatment of bleeding episodes (including treatment and prevention of those occurring during and after surgery).3 Long term efficacy has not been established.